Bvf Inc Buys Cytokinetics Inc, IDEAYA Biosciences Inc, Calithera Biosciences Inc, Sells Array BioPharma Inc, Arqule Inc, Blueprint Medicines Corp

• New Purchases: IDYA, AKRO, XFOR, KPTI, MREO, NVUS,
• Added Positions: CYTK, CALA, ACIU, MRTX, CTMX, RCUS, SPRO, VSTM, SNSS, CNCE, CRVS, EPIX, REPL, SURF, CDTX, MRUS, RGLS, SBPH, RLM, OVID, XOMA,
• Reduced Positions: ARRY, ARQL, BPMC, KURA, ALBO, GNCA, DRNA, MTEM, MEIP, SNDX, ANAB, FPRX, CCXI, PTGX, VICL, XENE, PIRS, GLMD, ALPN,
• Sold Out: ARGX, VBIV, VYGR, OMED, XNCR,

For the details of BVF INC's stock buys and sells, go to https://www.gurufocus.com/guru/bvf+inc/current-portfolio/portfolio

1. Merus NV (MRUS) - 4,639,413 shares, 7.54% of the total portfolio. Shares added by 2.19%
2. Cytokinetics Inc (CYTK) - 5,176,878 shares, 6.46% of the total portfolio. Shares added by 36.17%
3. Array BioPharma Inc (ARRY) - 1,193,224 shares, 6.13% of the total portfolio. Shares reduced by 65.12%
4. AC Immune SA (ACIU) - 9,819,434 shares, 6.04% of the total portfolio. Shares added by 31.71%
5. Mirati Therapeutics Inc (MRTX) - 527,253 shares, 6.02% of the total portfolio. Shares added by 22.13%

Bvf Inc initiated holding in IDEAYA Biosciences Inc. The purchase prices were between $9.58 and $11.95, with an estimated average price of $10.89. The stock is now traded at around $6.52. The impact to a portfolio due to this purchase was 1.66%. The holding were 1,505,429 shares as of .

Bvf Inc initiated holding in Akero Therapeutics Inc. The purchase prices were between $18.08 and $19.83, with an estimated average price of $18.95. The stock is now traded at around $28.80. The impact to a portfolio due to this purchase was 1.38%. The holding were 648,348 shares as of .

Bvf Inc initiated holding in X4 Pharmaceuticals Inc. The purchase prices were between $12.57 and $21.67, with an estimated average price of $16.91. The stock is now traded at around $12.60. The impact to a portfolio due to this purchase was 0.97%. The holding were 580,500 shares as of .

Bvf Inc initiated holding in Karyopharm Therapeutics Inc. The purchase prices were between $4.32 and $6.43, with an estimated average price of $5.35. The stock is now traded at around $9.27. The impact to a portfolio due to this purchase was 0.24%. The holding were 355,266 shares as of .

Bvf Inc initiated holding in Mereo BioPharma Group PLC. The purchase prices were between $2.52 and $6.5, with an estimated average price of $4.38. The stock is now traded at around $4.00. The impact to a portfolio due to this purchase was 0.14%. The holding were 523,382 shares as of .

Bvf Inc initiated holding in Novus Therapeutics Inc. The purchase prices were between $0.98 and $4.4, with an estimated average price of $2.45. The stock is now traded at around $0.79. The impact to a portfolio due to this purchase was 0.09%. The holding were 828,876 shares as of .

Bvf Inc added to a holding in Cytokinetics Inc by 36.17%. The purchase prices were between $7.95 and $11.25, with an estimated average price of $9.63. The stock is now traded at around $14.23. The impact to a portfolio due to this purchase was 1.72%. The holding were 5,176,878 shares as of .

Bvf Inc added to a holding in Calithera Biosciences Inc by 123.27%. The purchase prices were between $3.71 and $6.75, with an estimated average price of $5.68. The stock is now traded at around $4.03. The impact to a portfolio due to this purchase was 1.61%. The holding were 6,750,482 shares as of .

Bvf Inc added to a holding in AC Immune SA by 31.71%. The purchase prices were between $4.72 and $5.88, with an estimated average price of $5.09. The stock is now traded at around $5.70. The impact to a portfolio due to this purchase was 1.45%. The holding were 9,819,434 shares as of .

Bvf Inc added to a holding in Mirati Therapeutics Inc by 22.13%. The purchase prices were between $59.49 and $104.71, with an estimated average price of $77.61. The stock is now traded at around $89.90. The impact to a portfolio due to this purchase was 1.09%. The holding were 527,253 shares as of .

Bvf Inc added to a holding in CytomX Therapeutics Inc by 56.40%. The purchase prices were between $9.35 and $11.41, with an estimated average price of $10.49. The stock is now traded at around $9.33. The impact to a portfolio due to this purchase was 0.84%. The holding were 1,873,617 shares as of .

Bvf Inc added to a holding in Arcus Biosciences Inc by 25.80%. The purchase prices were between $7.29 and $13.38, with an estimated average price of $10.01. The stock is now traded at around $7.17. The impact to a portfolio due to this purchase was 0.64%. The holding were 3,535,223 shares as of .

Bvf Inc sold out a holding in argenx SE. The sale prices were between $115 and $141.58, with an estimated average price of $126.95.

Bvf Inc sold out a holding in VBI Vaccines Inc. The sale prices were between $0.65 and $2.12, with an estimated average price of $1.81.

Bvf Inc sold out a holding in Voyager Therapeutics Inc. The sale prices were between $19.18 and $27.88, with an estimated average price of $22.85.

Bvf Inc sold out a holding in OncoMed Pharmaceuticals Inc. The sale prices were between $0.89 and $1.16, with an estimated average price of $1.01.

Bvf Inc sold out a holding in Xencor Inc. The sale prices were between $29.6 and $40.93, with an estimated average price of $32.83.